Jim A. Julian

Jim A. Julian

Auto-generated profile, based on publicly available information

Jim A. Julian

Ontario Clinical Oncology Group, McMaster University, Hamilton, ON, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in BMJ
Verified
Journal Article
Open access
PDF file
CKClive Kearon
Clive Kearon
KWKerstin de Wit
Kerstin de Wit
SPSameer Parpia
Sameer Parpia
SSSam Schulman
Sam Schulman
FSFrederick A Spencer
Frederick A Spencer
JJJim A Julian
Jim A Julian
Objective To evaluate the safety and efficiency of a diagnostic algorithm for deep vein thrombosis (DVT) that uses clinical pretest probability based D-dimer thresholds to exclude DVT. Design Prospective diagnostic management study. Setting University based emergency departments or outpatient clinics in Canada. Participants Patients with symptoms or signs of DVT. Intervention DVT was considered excluded without further testing by Wells low clinical pretest probability and D-dimer <1000 ng/mL or Wells moderate clinical pretest probability and D-dimer 3000 ng/mL or high clinical pretest probability and D-dimer >1500 ng/mL. If DVT was not diagnosed, patients did not receive anticoagulant treatment. Main outcome measure Symptomatic venous thromboembolism at three months. Results 1508 patients were enrolled and analysed, of whom 173 (11.5%) had DVT on scheduled diagnostic testing. Of the 1275 patients with no proximal DVT on scheduled testing who did not receive anticoagulant treatment, eight (0.6%, 95% confidence interval 0.3% to 1.2%) were found to have venous thromboembolism during follow-up. Compared with a traditional DVT testing strategy, this diagnostic approach reduced the need for ultrasonography from a mean of 1.36 scans/patient to 0.72 scans/patient (difference −0.64, 95% confidence interval −0.68 to −0.60), corresponding to a relative reduction of 47%. Conclusions The diagnostic strategy using a combination of clinical pretest probability and D-dimer identified a group of patients at low risk for DVT during follow-up while substantially reducing the need for ultrasound imaging. Registration ClinicalTrials.gov NCT02038530.

5 September 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MKMonika K Krzyzanowska
Monika K Krzyzanowska
JJJim A. Julian
Jim A. Julian
MPMelanie Powis
Melanie Powis
Doris HowellDoris Howell
Doris Howell
CECraig C. Earle
Craig C. Earle
EGEva Grunfeld
Eva Grunfeld
Population-based studies suggest that emergency department visits and hospitalizations are common among patients receiving chemotherapy and that rates in routine practice are higher than expected from clinical trials. Chemotherapy-related toxicities are often predictable and, consequently, acute care visits may be preventable with adequate treatment planning and support between visits to the cancer centre. We will evaluate the impact of proactive telephone-based toxicity management on emergency department visits and hospitalizations in women with early stage breast cancer receiving chemotherapy. In this pragmatic covariate constraint-based cluster randomized trial, 20 centres in Ontario, Canada are randomly allocated to either proactive telephone toxicity management (intervention) or routine care (control). The primary outcome is the cluster-level mean number of ED + H visits per patient evaluated using Ontario administrative healthcare data. Participants are all patients with early stage (I-III) breast cancer commencing adjuvant or neo-adjuvant chemotherapy at participating institutions during the intervention period. At least 25 patients at each centre participate in a patient reported outcomes sub-study involving the collection of standardized questionnaires to measure: severity of treatment toxicities, self-care, self-efficacy, quality of life, and coordination of care. Patients participating in the patient reported outcomes (PRO) sub-study are asked to provide written consent to link their PRO data to administrative data. Unit costs will be applied to each per person resource utilized, and a total cost per population and patient will be generated. An incremental cost-effectiveness analysis will be undertaken to compare the incremental costs and outcomes between the intervention and control groups from the health system perspective. This study evaluates the effectiveness of a proactive toxicity management intervention in a routine care setting. The use of administrative healthcare data to evaluate the primary outcome enables an evaluation in a real world setting and at a much larger scale than previous studies. Clinicaltrials.gov , NCT02485678. Registered 30 June 2015.

18 January 2023 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Bojana PetrovicBojana Petrovic
Bojana Petrovic
JJJim A Julian
Jim A Julian
CLClare Liddy
Clare Liddy
AAAmir Afkham
Amir Afkham
SMSharon McGee
Sharon McGee
EGEva Grunfeld
Eva Grunfeld
Background: Cancer poses a significant global health burden. With advances in screening and treatment, there are now a growing number of cancer survivors with complex needs, requiring the involvement of multiple health care providers. Previous studies have identified problems related to communication and care coordination between primary care providers (PCPs) and cancer specialists. Objective: This study aimed to examine whether a web- and text-based asynchronous system (eOncoNote) could facilitate communication between PCPs and cancer specialists (oncologists and oncology nurses) to improve patient-reported continuity of care among patients receiving treatment or posttreatment survivorship care. Methods: In this pragmatic randomized controlled trial, a total of 173 patients were randomly assigned to either the intervention group (eOncoNote plus usual methods of communication between PCPs and cancer specialists) or a control group (usual communication only), including 104 (60.1%) patients in the survivorship phase (breast and colorectal cancer) and 69 (39.9%) patients in the treatment phase (breast and prostate cancer). The primary outcome was patient-reported team and cross-boundary continuity (Nijmegen Continuity Questionnaire). Secondary outcome measures included the Generalized Anxiety Disorder Screener (GAD-7), Patient Health Questionnaire on Major Depression, and Picker Patient Experience Questionnaire. Patients completed the questionnaires at baseline and at 2 points following randomization. Patients in the treatment phase completed follow-up questionnaires at 1 month and at either 4 months (patients with prostate cancer) or 6 months following randomization (patients with breast cancer). Patients in the survivorship phase completed follow-up questionnaires at 6 months and at 12 months following randomization. Results: The results did not show an intervention effect on the primary outcome of team and cross-boundary continuity of care or on the secondary outcomes of depression and patient experience with their health care. However, there was an intervention effect on anxiety. In the treatment phase, there was a statistically significant difference in the change score from baseline to the 1-month follow-up for GAD-7 (mean difference −2.3; P=.03). In the survivorship phase, there was a statistically significant difference in the change score for GAD-7 between baseline and the 6-month follow-up (mean difference −1.7; P=.03) and between baseline and the 12-month follow-up (mean difference −2.4; P=.004). Conclusions: PCPs’ and cancer specialists’ access to eOncoNote is not significantly associated with patient-reported continuity of care. However, PCPs’ and cancer specialists’ access to the eOncoNote intervention may be a factor in reducing patient anxiety. Trial Registration: ClinicalTrials.gov NCT03333785; https://clinicaltrials.gov/ct2/show/NCT03333785

21 March 2013 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
SPSameer Parpia
Sameer Parpia
LTLehana Thabane
Lehana Thabane
JJJim A Julian
Jim A Julian
TWTimothy J Whelan
Timothy J Whelan
MLMark Norman and Hinda Levine
Mark Norman and Hinda Levine
Subjects with breast cancer enrolled in trials may experience multiple events such as local recurrence, distant recurrence or death. These events are not independent; the occurrence of one may increase the risk of another, or prevent another from occurring. The most commonly used Cox proportional hazards (Cox-PH) model ignores the relationships between events, resulting in a potential impact on the treatment effect and conclusions. The use of statistical methods to analyze multiple time-to-event events has mainly been focused on superiority trials. However, their application to non-inferiority trials is limited. We evaluate four statistical methods for multiple time-to-event endpoints in the context of a non-inferiority trial.

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MLMark Norman and Hinda Levine
Mark Norman and Hinda Levine
BCBrandy Lynn Cochrane
Brandy Lynn Cochrane
JJJim A. Julian
Jim A. Julian
MTMaureen Trudeau
Maureen Trudeau
AEAndrea Eisen
Andrea Eisen
KPKathleen I. Pritchard
Kathleen I. Pritchard
583 Background: The OncotypeDX 21-gene assay (ODX) is used to aid in decision-making for chemotherapy (CT) in patients with breast cancer (BC). The province of Ontario, with a population of approximately 14 million, has a publically funded healthcare system. Funding of the ODX test by the Ontario Ministry of Health was conditional upon participation in a prospective cohort study by the Ontario Clinical Oncology Group to evaluate the test’s impact on decision making. Methods: Subjects with node– ER+ Her2– BC who were considered for CT in addition to usual endocrine therapy (ET) were eligible. The oncologist’s initial treatment recommendation based on the Adjuvant! Online (AO) result and classical factors (tumor size and grade) was recorded. Once the ODX recurrence score (RS) was available, the patient returned to clinic for final decision-making. Outcomes were the change in the oncologist’s treatment recommendation, change in patient’s treatment preference, and economics. AO relapse risk categories used in...

20 May 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EGEva Grunfeld
Eva Grunfeld
MLM. N. Levine
M. N. Levine
JJJ. A. Julian
J. A. Julian
GPGreg Pond
Greg Pond
EME. Maunsell
E. Maunsell
OGOntario Clinical Oncology Group
Ontario Clinical Oncology Group
9005 Background: Survivorship care plans (SCPs) are recommended for patients who have completed primary treatment and are transitioning to routine follow-up care. SCPs are considered to have face validity but have never been tested in a randomized trial. The objective of this study was to evaluative a SCP for breast cancer survivors transitioning to routine follow-up care with their own family physician (FP). Methods: 408 early -stage breast cancer patients who completed primary treatment at least 3 months previously and without recurrent or new primary cancer were enrolled through tertiary care cancer centers throughout Canada and stratified into 2 groups: <24 months (n=180) and ≥ 24 months (n=228) since diagnosis. All patients were transferred to their own FP for follow-up care. In the intervention group, 200 patients received a SCP consisting of: a treatment summary; a patient-version of follow-up guidelines; brochures and information about local relevant supportive care resources. These were compiled ...